Targeting enzymes for cancer therapy: Old enzymes in new roles

British Journal of Cancer

Volumn 70, Issue 5, 1994, Pages 786-794

  Deonarain, M P ^a   Epenetos, A A ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ALKALINE PHOSPHATASE; ANTIBODY; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BETA GLUCOSIDASE; BETA LACTAMASE; CARBOXYPEPTIDASE; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; CYTOSINE DEAMINASE; CYTOTOXIC AGENT; DOXORUBICIN; ENZYME; FLUCYTOSINE; GLUCOSE OXIDASE; GLUCURONIDE; HYBRID PROTEIN; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; NITROREDUCTASE; OXYGEN RADICAL; PALYTOXIN; PENICILLIN AMIDASE; PHOSPHODIESTERASE; PRODRUG; TUMOR ANTIGEN; XANTHINE OXIDASE;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG TARGETING; ENZYME THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

ANIMAL; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ENZYMES; HUMAN; IMMUNOTOXINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PRODRUGS;

EID: 0028154911     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1994.400     Document Type: Article

References (69)

1. ADAMS, G.P., MCCARTHY, J.E., TAI, M., OPPERMANN, H., HUSTON, J.S., STAFFORD, W.F., BROOKMAN, M.A., FAND, I., HOUSTON, L.L. & WEINER, L.M. (1993). Highly specific in vivo tumour targeting by monovalent and divalent forms of 741F8 anti-C- erbB2 single-chain Fv. Cancer Res., 53, 4026–4034.
2. ALEKSANDROWICZ, J. (1958). Intracutaneous ribonuclease in chronic myeloid leukaemia. Lancet, 307, 420–426.
3. ALEXANDER, R.P., BEELEY, N., ODRISCOLL, M., ONEILL, F.P., PRATT, A. & WILLENBROCK, F.W. (1991). Cephalosporin nitrogen mustard carbamate prod rugs for ADEPT. Tetrahedron. Lett., 32, 3269–3272.
4. ANLEZARK, G.M., MELTON, R.G., SHERWOOD, R.F., COLES, B., FRIEDLOS, F. & KNOX, R.J. (1992). The bioactivation of 5- (aziridin-l-YL)-2,4-dinitrobenzamide (CB1954). I. Purification and properties of a nitroreductase enzyme from E. coli-a. potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol., 44, 2289–2295.
5. BAGSHAWE, K.D. (1987). Antibody directed enzymes revive anticancer prodmgs concept. Br. J. Cancer, 56, 531–532.
6. BAGSHAWE, K.D., SPRINGER, C.J., SEARLE, F., ANTONIW, P., SHARMA, S.K., MELTON, R.G & SHERWOOD, R.F. (1988). A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer, 58, 700–703.
7. BAGSHAWE, K.D., SHARMA, S.K., SPRINGER, C.J., ANTONIW, P., ROGERS, G.T., BURKE, P.J., MELTON, R.G. & SHERWOOD, R.F. (1991). Antibody-enzyme conjugates can generate cytotoxic drugs from inactive precursors at tumour sites. Antibody 1mm. Radiopharm., 4, 915–922.
8. BIGNAMI, G.S., SENTER, P.D., GROTHAUS, P.G., FISCHER, K.J., HUMPHREYS, T. & WALLACE, P.M. (1992). N-(4'- Hydroxyphenylacetyl) palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody - penicillin G-amidase conjugate. Cancer Res., 52, 5759–5764.
9. BIRD, K.D., HARDMAN, K.D., JACOBSON, J.W., JOHNSON, S., KAUFMAN, B.M., LEE, S.M., LEE, T., POPE, S.H., RIORDAN, G.S. & WHITLOW, M. (1988). Single-chain antigen binding proteins. Science, 242, 423–426.
10. BOSSLET, K., CZECH, J., LORENZ, P., SEDLACEK, H.H., SCHUER-MANN, M. & SEEM AN, G. (1992). Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br. J. Cancer, 65, 238–243.
11. BOSSLET, K., CZECH, J. & HOFFMANN, D. (1994). Tumour-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res., 54, 2151–2159.
12. BYERS, V S., RODVIEN, R., GRANT, K., DURRANT, L.J., HUDSON, K.H., BALDWIN, R.W. & SCANNON, P.J. (1989). Phase I study of a monoclonal antibody-ricin A chain immunotoxin (Xomazyme- 791) in patients with metastatic colon cancer. Cancer Res., 49, 6153–6160.
13. CHESTER, K.A., BEGENT, R.H.J., ROBSON, L., KEEP, P., PEDLEY, R.B., BODEN, J.A., BOXER, G., GREEN, A., WINTER, G., CROCHET, O. & HAWKINS, R E. (1994). Phage libraries for generation of clinically useful antibodies. Lancet, 343, 455–456.
14. CONNORS, T.A. & WHISSON, M.E. (1966). Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature, 210, 866–867.
15. 1311-9.2.27 monoclonal antibody in human malignant melanoma. Cancer Res., 49, 2783–2789.
16. DEONARAIN, M.P. & EPENETOS, A.A. (1994). Targeting phosphodiesterases as a strategy for killing tumour cells. Cell Biophys. (Suppl.) (in press).
17. DINOTA, A., TAZZARI, P L., ABBONDANZA, A., BATELLI, M.G., GOBBI, M. & STIRPE, F. (1990). Bone marrow purging by an oxidase-antibody conjugate. Bone Marrow Transplant., 6, 31–36.
18. EDWARDS, P.A.W. (1985). Heterogeneous expression of cell surface antigens in normal epithelia and their tumours revealed by monoclonal antibodies. Br. J. Cancer, 51, 149–160.
19. EPENETOS, A.A., SNOOK, D., HOOKER, G., BEGENT, R., DURBIN, H., OLIVER, R.T.D., BODMER, W.F. & LAVENDER, J.P. (1985). Indium-111-labelled monoclonal antibody to placental alkaline phosphatase in the detection of neoplasms of the testis, ovary and cervix. Lancet, 326, 350–353.
20. EPENETOS, A.A., SNOOK, D., DURBIN, H., JOHNSON, P.M. & TAYLOR-PAPADIMITRIOU, J. (1986). Limitations of radiolabelled monoclonal antibodies for localisation of human neoplasms. Cancer Res., 46, 3183–3191.
21. GLENNIE, M.J., BRENNAND, D.M., BRYDEN, F., MCBRIDE, H.M., STIRPE, F., WORTH, A.T. & STEVENSON, G.T. (1988). Bispecific F(ab'y)2 antibody for the delivery of saporin in the treatment of lymphoma. J. Immunol., 141, 3662–3670.
22. GLUKHOV, B.N., JERUSALIMSKY, A.P., CANTER, V.M. & SAL-GANIK, R.I. (1976). Ribonuclease treatment of tick-borne encephalitis. Arch. Neurol., 33, 598–605.
23. GOULD, B.J., BOROWITZ, M.J., GROVES, E.S., CARTER, P.W., ANTHONY, D., WEINER, L.M. & FRANKEL, A.E. (1989). Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J. Natl Cancer Inst., 81, 775–781.
24. GUTIEREZ, A.A., LEMOINE, N.R. & SIKORA, K. (1992). Gene therapy for cancer. Lancet, 339, 715–721.
25. HAENSELER, E., ESSWEIN, A., VITOLS, K.S., MONTEJANO, Y., MUELLER, B.M., REISFELD, R.A. & HUENNKENS, F.M. (1992). Activation of methotrexate ot-alanine by carboxypeptidase A- monoclonal antibody conjugate. Biochemistry, 31, 891–897.
26. HAISMA, H.J., BOVEN, E., VAN-MUUEN, M., DE VRIES, R. & PINEDO, H.M. (1992a). Analysis of a conjugate between carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immunol. Immunother., 34, 343–348.
27. HAISMA, H.J., BOVEN, E., VAN MUUEN, M., DE JONG, J., VAN DER VUGH, W.J.F. & PINEDO, H.M. (1992b). A monoclonal antibody ß-glucuronidase conjugate as activator of the prodrug epirubicin- glucuronide for specific treatment of cancer. Br. J. Cancer, 66, 474–478.
28. HARRIS, J.D.H., GUTIEREZ, A.A., HURST, H.C., SIKORA, K. & LEMOINE, N.R. (1994). Gene therapy for carcinoma using tumour specific prodrug activation. Gene Ther., 1, 170–175.
29. HUSTON, J.S., LEVINSON, D., MUDGETT-HUNTER, M., TAI, M.S., NOVOTNY, J., MARGOLIES, M.N., RIDGE, R.J., BRUCCOLERI, R.E., HABER, E., CREA, R. & OPPERMANN, H. (1988). Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in E. coli. Proc. Natl &cad. Sei. USA, 85, 5879–5883.
30. ITO, H., MORIZET, J., COLOMBEL, L. & STANISLAWSKI, M. (1990). T cell depletion of human bone marrow using an oxidaseperoxidase enzyme immunotoxin. Bone Marrow Transplant., 6, 395–398.
31. KERR, D.E., SENTER, P.D., BURNETT, W.V., HIRSCHBERG, D.L., HELLSTRÖM, I. & HELLSTRÖM, K.E. (1990). Antibody-penicillin V-amidase conjugates kill antigen positive tumour cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol. Immunother., 31, 202–206.
32. KÖHLER, G. & MILSTEIN, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 245, 495–497.
33. LACCETTI, P., PORTELLA, G., MASTONICOLA, M R., RUSSO, A., PICCOLI, R., D’ALLESSIO, G. & VECCHIO, G. (1992). In vivo and in vitro growth-inhibitory effect of bovine seminal ribonuclease on a sytem of rat thyroid epithelial transformed cells and tumours. Cancer Res., 52, 4582–4589.
34. LEDERMAN, J.A., BEGENT, R.H.J., BAGSHAWE, K.D., RIGGS, S.J., SEARLE, F., GLASER, M.G., GREEN, A.J. & DALE, R.G. (1988). Repeated anti-tumour antibody therapy in man with suppression of the host response by cyclosporin A. Br. J. Cancer, 58, 654–657.
35. MARASCO, W.A., HASELTINE, W.A. & CHEN, S. (1993). Design, intracellular expression and activity of a human anti-human immunodeficiency virus type gpl20 single-chain antibody. Proc. Natl Acad. Sci. USA, 90, 7889–7893.
36. MARTIN, S.J., GREEN, D.R. & COTTER, T.G. (1994). Dicing with death: dissecting the components of the apoptosis machinery. Trends Biochem. Sci., 19, 26–30.
37. MEYER, D.L., JUNGHEIM, L.N., MIKOLAJCZAK, S.D., SHEPHERD, T.A., STARLING, J.J. & AHLEM, C.N. (1992). Preparation and characterisation of a 0-lactamase-Fab’ conjugate for the site- specific activation of oncolytic agents. Bioconjugate Chem., 3, 42–48.
38. MIKULSKI, S.M., VIERA, A. & SHOGEN, K. (1992). In vitro synergism between a novel amphibian oocyte ribonuclease (Onconase®) and tamoxifen, lovastatin and cisplatin, in human OVCAR-3 ovarian cancer cell-line. Int. J. Oncol., 1, 779–785.
39. MIYASHITA, H., KARAKI, Y., KIKUCHI, M. & FUJII, I. (1993). Prodrug activation by catalytic antibodies. Proc. Natl Acad. Sci. USA, 90, 5337–5340.
40. MOOLTEN, F.L. (1986). Tumour chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46, 5276–5281.
41. MULLEN, C.A., KILSTRUP, M. & BLAESE, R.M. (1992). Transfer of the bacterial gene for cytosine deaminase to mammalian cells confer lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl Acad. Sci. USA, 89, 33–37.
42. MUZYKANTOV, V.R., SAKHAROV, D.V., SINITSYN, V.V., DOMOGATSKY, S.P., GONCHAROV, N.V. & DANILOV, S.M. (1988). Specific killing of human endothelial cells by antibody- conjugated glucose oxidase. Anal. Biochem., 169, 383–389.
43. MUZYKANTOV, V.R., TRUBETKAYA, O.V., PUCHNINA, E.A., SAKHAROV, D.V. & DOMOGATSKY, S.P. (1990). Cytotoxicity of glucose oxidase conjugated with antibodies to target cells: killing efficiency depends on the conjugate internalisation. Biochim. Biophys. Acta, 1053, 27–31.
44. NEUBERGER, M.S., WILLIAMS, G.T. & FOX, R.O. (1984). Recombinant antibodies possessing novel effector functions. Nature, 312, 604–609.
45. NEWTON, D.L., ILERCIL, O., LASKE, D.W., OLDFIELD, E., RYBAK, S.M. & YOULE, R.J. (1992). Cytotoxic ribonuclease chimeras. J. Biol. Chem., 267, 19572–19578.
46. PHILPOTT, G.W., SHEARER, W.T., BOWER, R.W. & PARKER, C.W. (1973). Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate. J. Immunol., III, 921–929.
47. RIECHMANN, L., CLARK, M R., WALDMANN, H. & WINTER, G. (1988). Reshaping human antibodies for therapy. Nature, 332, 323–327.
48. ROFFLER, S R., WANG, S.M., CHERN, J.W., YEH, M.Y. & TUNG, E. (1991). Anti-neoplastic glucuronide prod rug treatment of human tumour cells targeted with a monoclonal antibody-enzyme conjugate. Biochem. Pharmacol., 42, 2062–2065.
49. ROWLINSON-BUSZA, G., BAM IAS, A., KRAUS, T. & EPENETOS, A.A. (1991). Antibody-guided enzyme nitrile therapy (Agent): in vitro cytotoxicity and in vivo tumour localisation. In Monoclonal antibodies. Applications in Clinical Oncology Epenetos, A.A. (ed.) pp. 111-118. Chapman & Hall: London.
50. RYBAK, S.M., SAXENA, S.K., ACKERMAN, E.J. & YOULE, R.J. (1991). Cytotoxic potential of ribunuclease and ribonclease hybrid proteins. J. Biol. Chem., 266, 21202–21207.
51. RYBAK, S.M., HOOGENBOOM, H.R., MEADE, H.M., RAUS, J.C.M., SCHWARTZ, D. & YOULE, R.J. (1992). Humanisation of immunotoxins. Proc. Natl Acad. Sci. USA, 89, 3165–3169.
52. SAHIN, U., HARTMANN, F., SENTER, P., POHL, C., ENGERT, A., DIEHL, V. & PFEUNDSCHUN, M. (1990). Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti- alkaline phosphatase monoclonal antibody. Cancer Res., 50, 6944–6948.
53. SAKHAROV, D.V., MUZYKANTOV, V.R., DOMOGATSKY, S.P. & DANILOV, S.M. (1987). Protection of cultured endothelial cells from hydrogen peroxide-induced injury by antibody-conjugated catalase. Biochim. Biophys. Acta, 930, 140–144.
54. SENTER, P.D., SAULNIER, M.G., SCHREIBER, G.J., HIRSCHIBERG, D.L., BROWN, J.P., HELLSTROM, I. & HELLSTROM, K.E. (1988). Anti-tumour effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl Acad. Sci USA, 85, 4842–4846.
55. SENTER, P.D., SU, P.C.D., KATSURAGI, T., SAKAI, T., COSSAND, W.L., HELLSTRÖM, I. & HELLSTRÖM, K.E. (1991). Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody- cytosine deaminase conjugates. Bioconjugate Chem., 2, 447–451.
56. SEHON, A.H. (1989). Modulation of antibody response by conjugation to antigens with monoethoxypolvethylene glycol. Adv. Exp. Med. Biol., 251, 341–351.
57. SHARMA, S.K., BAGSHAWE, K.D., SPRINGER, C.J., BURKE, P.J., ROGERS, G.T., BODEN, J.A., ANTONIW, P., MELTON, R.G. & SHERWOOD, R.F. (1991). Dis. Markers, 9, 225–231.
58. SPRINGER, C.J., BAGSHAWE, K.D., SHARMA, S.K., SEARLE, F., BODEN, J.A., ANTONIW, P., BURKE, P.J., GORDON, T.R., SHERWOOD, R.F. & MELTON, R.G. (1991). Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prod rug therapy (ADEPT) with three novel compounds. Eur. J. Cancer. T7, 1361–1366.
59. STANISLAWSKI, M., ROUSSEAU, V., COAVEC, M. & ITO, H. (1989). Immunotoxins containing glucose oxidase and lactoperoxidase with tumouricidal properties. In vitro killing effectiveness in a mouse plasmacytoma cell model. Cancer Res., 49, 5497–5504.
60. UNTERS, A., BAER, J. & BAGSHAWE, K.D. (1991). Cytotoxicity and activation of CB1954 in a human tumour cell line. Biochem. Pharmacol., 41, 1293–1298.
61. SVENSSON, H.P., KADOW, J.F., VRUDHULA, V.M., WALLACE, P.M. & SENTER, P.D. (1992). Monoclonal antibody-ß-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconjugate Chem., 3, 176–181.
62. TANNOCK, I.F. & RATIN, P. (1989). Acid pH in tumours and its potential in therapeutic exploitation. Cancer Res., 49, 4373–4384.
63. VALERIOTE, F. & PUTTEN, L. (1975). Proliferation-dependent cytotoxic action of anti-cancer agents: a review. Cancer Res., 35, 2619–2630.
64. VINGERHOEDS, M H., HAISMA, H.J., VAN MUUEN, M., VAN DE RIJT, R.B.J., CROMMELIN, D.J.A. & STORM, G. (1993). A new application for liposomes in cancer therapy. FEBS Lett., 336, 485–490.
65. VTTETTA, E.S., THORPE, P.E. & UHR, J.W. (1993). Immunotoxins: magic bullets or misguided missiles: Trends Pharmacol. Sei., 14, 148–154.
66. WALDMANN, T.A. (1991). Monoclonal antibodies in diagnosis and therapy. Science. 252, 1657–1662.
67. WEINER, L.M., O’DWYER, J., KITSON, J., COMIS, R.L., FRANKEL, A.E., BAUER, RJ., KONRAD, M.S. & GROVES, E.S. (1989). Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res., 49, 4062–4067.
68. WORRALL, A.F. & CONNOLLY, B.A. (1990). The chemical synthesis of a gene codong for bovine pancreatic DNase I and its cloning and expression in Escherichia coli. J. Biol. Chem., 265, 21889–21895.
69. WU, Y., MIKULSKI, S.M., ARDELT, W., RYBAK, S.M. & YOULE, R.J. (1991). A cytotoxic ribonuclease. J. Biol. Chem., 268, 10686–10693.